Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY: NVS )

110.13 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 636
Open 110.13
Bid (Size) 111.49 (8)
Ask (Size) 111.57 (8)
Prev. Close 110.13
Today's Range 110.13 - 110.13
52wk Range 96.06 - 120.92
Shares Outstanding N/A
Dividend Yield 3.43%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs
Roche to invest $50 billion in U.S. over five years, adding 12,000+ jobs and expanding manufacturing, R&D, and export capacity across eight states. 
Via Benzinga
S&P 500, Nasdaq Futures Rise After Stocks Dip Amid Trump's Jabs At Powell, Strong Yen Gives Nikkei A Volatile Start
U.S. stock futures rose Monday night even as Wall Street had a rough start to the week, amid growing concerns regarding the Federal Reserve's independence, and President Donald Trump's repeated attacks... 
Via Benzinga
Topics Economy Government Stocks
Exposures Interest Rates Political US Equities

Performance

YTD
+13.37%
+13.37%
1 Month
-0.86%
-0.86%
3 Month
+12.18%
+12.18%
6 Month
-3.45%
-3.45%
1 Year
+13.21%
+13.21%

More News

Read More
3 Momentum Stocks That Could Soar Post-Market Volatility
Via MarketBeat
Topics Artificial Intelligence World Trade
Exposures Artificial Intelligence Product Safety Tariff
Food for Thought: Results from a Food Allergy Survey of Caregivers
Via Brandpoint
2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
Mr. Ethan Billings recommends paying close attention to biotech stocks
Via Binary News Network
Novartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties
Via Benzinga
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
Via Benzinga
Topics Government Supply Chain World Trade
Exposures Political Supply Chain Tariff
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst
Via Benzinga
Topics World Trade
Exposures Tariff
3 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year
Via Benzinga
Exposures Product Safety
Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug Approval
Via Investor's Business Daily
Exposures Product Safety
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
Via Benzinga
Exposures Product Safety
The Top 3 Vanguard ETFs of 2025 (so Far) Share This 1 Striking Common Denominator
Via The Motley Fool
Topics Bonds ETFs
Exposures Debt Markets
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) Technical Analysis observations.
Via Chartmill
No Fear And No Panic After A 10% Correction = No Bottom
Via Talk Markets
Topics Stocks / Equities
FDA OKs Novartis Prostate Cancer Treatment, Triples Eligible Patient Pool
Via Benzinga
Exposures Product Safety
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) is an undervalued gem with solid fundamentals.
Via Chartmill
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
Via Benzinga
Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements
Via FinancialNewsMedia
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
Via Benzinga
Exposures Product Safety
Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders
Via Benzinga
Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy
Via Benzinga
The Best Vanguard ETF to Invest $1,000 in Right Now
Via The Motley Fool
Topics ETFs
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.